Guidelines for therapy of autoimmune liver disease

  • H. I
  • A. K
  • S. S
  • et al.
N/ACitations
Citations of this article
1Readers
Mendeley users who have this article in their library.

Abstract

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases. Copyright 2007 by Thieme Medical Publishers, Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

H., I., A., K., S., S., & M.E., G. (2007). Guidelines for therapy of autoimmune liver disease. Seminars in Liver Disease. H. Ishibashi, Clinical Research Center, National Hospital Organization (NHO), Nagasaki Medical Center, Kubara 2-1001-1, Omura, Nagasaki, 856-8562, Japan: Thieme Medical Publishers, Inc. Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=2007275357

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free